Connection

THOMAS MONATH to Yellow Fever Vaccine

This is a "connection" page, showing publications THOMAS MONATH has written about Yellow Fever Vaccine.
Connection Strength

8.096
  1. Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16; 387(10028):1599-600.
    View in: PubMed
    Score: 0.506
  2. Yellow fever. J Clin Virol. 2015 Mar; 64:160-73.
    View in: PubMed
    Score: 0.457
  3. 17D Yellow Fever Virus Vaccine. Am J Trop Med Hyg. 2013 Dec; 89(6):1225.
    View in: PubMed
    Score: 0.429
  4. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012 Apr; 11(4):427-48.
    View in: PubMed
    Score: 0.382
  5. Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
    View in: PubMed
    Score: 0.369
  6. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
    View in: PubMed
    Score: 0.363
  7. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
    View in: PubMed
    Score: 0.357
  8. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010 May; 82(5):919-21.
    View in: PubMed
    Score: 0.335
  9. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
    View in: PubMed
    Score: 0.332
  10. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
    View in: PubMed
    Score: 0.283
  11. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot. 2006 Dec; 99(5):341-7.
    View in: PubMed
    Score: 0.264
  12. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.251
  13. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005 Oct; 18(5):387-94.
    View in: PubMed
    Score: 0.244
  14. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
    View in: PubMed
    Score: 0.242
  15. Yellow fever vaccine. Expert Rev Vaccines. 2005 Aug; 4(4):553-74.
    View in: PubMed
    Score: 0.241
  16. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
    View in: PubMed
    Score: 0.233
  17. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
    View in: PubMed
    Score: 0.219
  18. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.212
  19. Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever. Clin Infect Dis. 2023 08 22; 77(4):565-573.
    View in: PubMed
    Score: 0.211
  20. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients. Clin Immunol. 2023 06; 251:109321.
    View in: PubMed
    Score: 0.205
  21. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
    View in: PubMed
    Score: 0.199
  22. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
    View in: PubMed
    Score: 0.192
  23. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002 May 15; 34(10):1369-78.
    View in: PubMed
    Score: 0.192
  24. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 2002 Jan 15; 20(7-8):996-9.
    View in: PubMed
    Score: 0.188
  25. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
    View in: PubMed
    Score: 0.188
  26. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
    View in: PubMed
    Score: 0.176
  27. Yellow Fever Remains a Potential Threat to Public Health. Vector Borne Zoonotic Dis. 2016 08; 16(8):566-7.
    View in: PubMed
    Score: 0.129
  28. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
    View in: PubMed
    Score: 0.091
  29. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
    View in: PubMed
    Score: 0.080
  30. Yellow fever recommendations for tourists to Kenya: a flawed risk assessment. J Travel Med. 2009 Mar-Apr; 16(2):146; author reply 146-7.
    View in: PubMed
    Score: 0.077
  31. Yellow fever: 100 years of discovery. JAMA. 2008 Aug 27; 300(8):960-2.
    View in: PubMed
    Score: 0.075
  32. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007 Apr 12; 25(15):2758-65.
    View in: PubMed
    Score: 0.066
  33. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.057
  34. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
    View in: PubMed
    Score: 0.050
  35. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
    View in: PubMed
    Score: 0.047
  36. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
    View in: PubMed
    Score: 0.047
  37. Yellow fever: an update. Lancet Infect Dis. 2001 Aug; 1(1):11-20.
    View in: PubMed
    Score: 0.046
  38. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001 Jul 14; 358(9276):91-7.
    View in: PubMed
    Score: 0.045
  39. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.